[Clinical-pharmacological aspects of the evaluation of digitalis effect].
D000251:Adenosine Triphosphatases / Q000378:metabolism; D000818:Animals; D001798:Blood Proteins; D003327:Coronary Disease / Q000188:drug therapy*; D003864:Depression, Chemical; D004071:Digitalis Glycosides / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects*; D006333:Heart Failure / Q000188:drug therapy*; D006334:Heart Function Tests; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D009206:Myocardium / Q000032:analysis / Q000201:enzymology / Q000378:metabolism; D011188:Potassium / Q000378:metabolism; D011485:Protein Binding; D012964:Sodium / Q000032:analysis; D013268:Stimulation, Chemical; D013328:Strophanthins / Q000494:pharmacology
D001798:Blood Proteins; D004071:Digitalis Glycosides; D013328:Strophanthins; D012964:Sodium; D000251:Adenosine Triphosphatases; D011188:Potassium
Klinisch-pharmakologische Aspekte zur Beurteilung der Digitalis-Wirkung.